THERIVA BIOLOGICS INC (TOVX) Stock Price & Overview

NYSEARCA:TOVXUS87164U5083

Current stock price

0.1752 USD
-0.01 (-3.2%)
At close:
0.1757 USD
+0 (+0.29%)
After Hours:

The current stock price of TOVX is 0.1752 USD. Today TOVX is down by -3.2%. In the past month the price decreased by -2.94%. In the past year, price decreased by -84.82%.

TOVX Key Statistics

52-Week Range0.1628 - 1.5
Current TOVX stock price positioned within its 52-week range.
1-Month Range0.1628 - 0.2591
Current TOVX stock price positioned within its 1-month range.
Market Cap
6.253M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-5.87
Dividend Yield
N/A

TOVX Stock Performance

Today
-3.2%
1 Week
-3.10%
1 Month
-2.94%
3 Months
-19.37%
Longer-term
6 Months -57.81%
1 Year -84.82%
2 Years -98.51%
3 Years -99.00%
5 Years N/A
10 Years N/A

TOVX Stock Chart

THERIVA BIOLOGICS INC / TOVX Daily stock chart

TOVX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to TOVX. When comparing the yearly performance of all stocks, TOVX is a bad performer in the overall market: 94.97% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TOVX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to TOVX. TOVX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TOVX Earnings

Next Earnings DateMay 12, 2026
Last Earnings DateMar 4, 2026
PeriodQ3 / 2025
EPS Reported-$0.45
Revenue Reported
EPS Surprise 41.57%
Revenue Surprise %

TOVX Forecast & Estimates

8 analysts have analysed TOVX and the average price target is 7.14 USD. This implies a price increase of 3975.34% is expected in the next year compared to the current price of 0.1752.


Analysts
Analysts80
Price Target7.14 (3975.34%)
EPS Next Y84.58%
Revenue Next YearN/A

TOVX Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

TOVX Financial Highlights

Over the last trailing twelve months TOVX reported a non-GAAP Earnings per Share(EPS) of -5.87. The EPS increased by 69.53% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-26.19M
Industry RankSector Rank
PM (TTM) N/A
ROA -84.93%
ROE -388.69%
Debt/Equity 0.25
Chartmill High Growth Momentum
EPS Q2Q%93.39%
Sales Q2Q%N/A
EPS 1Y (TTM)69.53%
Revenue 1Y (TTM)N/A

TOVX Ownership

Ownership
Inst Owners3.68%
Shares35.69M
Float34.95M
Ins Owners0%
Short Float %16.12%
Short Ratio0.48

TOVX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.8398.492B
AMGN AMGEN INC16.04198.265B
GILD GILEAD SCIENCES INC16.4180.267B
VRTX VERTEX PHARMACEUTICALS INC24.21121.459B
REGN REGENERON PHARMACEUTICALS15.9578.932B
ALNY ALNYLAM PHARMACEUTICALS INC42.0142.071B
INSM INSMED INC N/A30.073B
BIIB BIOGEN INC11.2927.136B
NTRA NATERA INC N/A26.973B
UTHR UNITED THERAPEUTICS CORP17.9523.353B
MRNA MODERNA INC N/A21.086B
EXAS EXACT SCIENCES CORP340.7419.713B
RVMD REVOLUTION MEDICINES INC N/A18.84B

About TOVX

Company Profile

TOVX logo image Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 22 full-time employees. The firm is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Company Info

IPO: 1993-02-12

THERIVA BIOLOGICS INC

9605 Medical Center Drive, Suite 270

Rockville MARYLAND US

Employees: 22

TOVX Company Website

TOVX Investor Relations

Phone: 17343327800

THERIVA BIOLOGICS INC / TOVX FAQ

What does THERIVA BIOLOGICS INC do?

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 22 full-time employees. The firm is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.


What is the current price of TOVX stock?

The current stock price of TOVX is 0.1752 USD. The price decreased by -3.2% in the last trading session.


Does THERIVA BIOLOGICS INC pay dividends?

TOVX does not pay a dividend.


What is the ChartMill technical and fundamental rating of TOVX stock?

TOVX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the employee count for TOVX stock?

THERIVA BIOLOGICS INC (TOVX) currently has 22 employees.


What is THERIVA BIOLOGICS INC worth?

THERIVA BIOLOGICS INC (TOVX) has a market capitalization of 6.25M USD. This makes TOVX a Nano Cap stock.


Can you provide the short interest for TOVX stock?

The outstanding short interest for THERIVA BIOLOGICS INC (TOVX) is 16.12% of its float.